Preempt future health risks.
Bill Emmott, former Editor-in-Chief at The Economist, joins Airfinity’s advisory board as the company expands its global public health data offering.Read More →
The Washington Post | Jan 27, 2023China celebrates lunar new year as Covid infections hit 80%
Financial Times | Jan 22, 2023China plays down COVID outbreak with holiday rush at full tilt
Reuters | Jan 20, 2023Covid-19 has already torn through large swathes of China
The Economist | Jan 19, 2023
View All →
What's happening in a given disease area?
Airfinity is the most comprehensive, single source of intelligence for new developments in your chosen area.
Identify the true need for a vaccine or a treatment.
Our suite of dynamic predictive indicators help you navigate highly dynamic and uncertain market developments and see the real opportunities.
Maximise impact to save lives
Our analytics and probabilistic tools inform key decisions on resource allocation, investment and procurement decisions to maximise impact of a given drug or vaccine and ultimately improve as many lives as possible.
Airfinity combines proprietary surveillance tools and forecast models with expert analysis for dozens of infectious diseases, including COVID-19, Monkeypox, Influenza and RSV.
Market & Production
Disease & Prevalence
“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”
Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister
“Airfinity has been instrumental in our country's COVID response.”
Head of UK Government
Vaccine Task Force
“Vaccine production data from Airfinity has been spot on. In a fast moving pandemic, these forecasts are really important for evidence-based policy making.”
“Airfinity has been critical in furnishing us and the rest of the world with COVID-19 numbers.”
James Fransham, Data Journalist,